Add To Watchlist
Share URL
About The Company
CEO
Ms. Renee Aguiar-Lucander
Market Cap
461.04 Million USD
Sector
Healthcare
Website
https://www.calliditas.seDescription
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases.
Read More
Overview
Value
1
Growth
12
Health
66
Management
19
Analyst Opinion
71
Total
32
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Has a low level of debt
- Has a history of share buybacks
- Has strong financial health
- Liked by analysts
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Income is not covering expenditure and investment
- Earnings are negative 0
- No margin of safety at their current market price
- Disliked by Twitter users
- Poor earnings and cashflow growth 0
Latest News

Calliditas Therapeutics: Good Long-Term Data Could Boost Tarpeyo Sales
Seeking Alpha | 12:34 Wed 12 Apr 2023
Read More →

Calliditas to participate in upcoming investor conferences
PRNewsWire | 17:20 Fri 31 Mar 2023
Read More →

3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing
The Motley Fool | 11:24 Sun 19 Mar 2023
Read More →

New Strong Sell Stocks for February 27th
Zacks Investment Research | 14:02 Mon 27 Feb 2023
Read More →
Market Peers
CALT
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-120.85%
Revenue Growth (5 Year Average)
N/A
Ratings Consensus
Buy
Share Buybacks
1.16%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
1
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 17.2 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-6.25%
PE/Earnings Growth
N/A
Price/Book
0.60x
Growth
Growth Score
12
- ✔ Revenue growth has improved this yeara
- ✔ Earnings growth has improved this year
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of 5.76% is lower than the market average (14.48%)
- ✘ 5 Year Average Free Cashflow growth of -15.24% is lower than the market average (12.35%)
Revenue Growth
N/A
Earnings Growth
5.76%
Cashflow Growth
-15.24%
Health
Health Score
66
Altman Z Score
N/A
Piostroski Score
3.00
Debt/Equity
0.95x
Current Assets/Liabilities
4.34x
Free Cashflow/Total Debt
0.32x
Debt/Capital
0.52x
Management
Management Score
19
Average Buybacks/Dilution
1.16%
Recent Buybacks/Dilution
0.78%
5 Year Price Volitility
25.20%
Return On Assets
-0.19%
Return On Capital Employed
-0.54%
Return On Equity
-0.49%
Return On Free Cashflow
3.01%
Return On Investments
-33.52%
Analysts
Analyst Opinion
71
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Calliditas Therapeutics AB (publ)
Currency
USD
Beta
1.295182
Vol Avg
11053
Ceo
Ms. Renee Aguiar-Lucander
Cik
0001795579
Cusip
13124Q106
Exchange
NASDAQ Global Select
Full Time Employees
98
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2020-06-05
Address
Kungsbron 1, C8
City
Stockholm
State
Country
SE
Zip
111 22
Phone
46 84 11 30 05
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
23
Twitter Sentiment
N/A
Stocktwits Sentiment
45.00